董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Itai Arkin | 男 | Director | 37 | 未披露 | 未持股 | 2026-03-19 |
| Hani Lerman | 女 | Director | 53 | 未披露 | 未持股 | 2026-03-19 |
| Yuval Yanai | 男 | Independent Director | 74 | 未披露 | 未持股 | 2026-03-19 |
| Moshe Arkin | 男 | Executive Chairman of the Board and interim Chief Executive Officer | 73 | 未披露 | 未持股 | 2026-03-19 |
| Ran Gottfried | 男 | Lead Independent Director | 81 | 未披露 | 未持股 | 2026-03-19 |
| Sharon Kochan | 男 | Independent Director | 58 | 未披露 | 未持股 | 2026-03-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ofer Toledano | -- | Vice President Research and Development | 61 | 38.30万 | 未持股 | 2026-03-19 |
| Ofra Levy Hacham | 男 | Vice President Clinical, Regulatory Affairs and Quality | 60 | 33.00万 | 未持股 | 2026-03-19 |
| Itzik Yosef | 男 | Chief Operating Officer | 49 | 29.30万 | 未持股 | 2026-03-19 |
| Michael Glezin | 男 | Chief Business Officer | 44 | 30.50万 | 未持股 | 2026-03-19 |
| Eyal Ben Or | 男 | Chief Financial Officer | 42 | 28.30万 | 未持股 | 2026-03-19 |
| Moshe Arkin | 男 | Executive Chairman of the Board and interim Chief Executive Officer | 73 | 未披露 | 未持股 | 2026-03-19 |
董事简历
中英对照 | 中文 | 英文- Itai Arkin
-
Itai Arkin在我们的首次公开募股定价后立即成为我们的董事会成员。Itai Arkin先生目前担任Arkin Holdings Ltd.的投资经理和Exalenz Bioscience Ltd.的董事会成员。Itai Arkin自2014年3月起担任以色列领先的医疗科技投资公司AccelMed和领先的梦百合对冲基金Sphera Global梦百合的投资委员会成员。Itai Arkin先生拥有以色列赫兹利亚跨学科中心工商管理学士学位和特拉维夫大学工商管理硕士学位（优等生）。Itai Arkin先生是我们董事会主席Moshe Arkin先生的儿子，也是我们控股股东Arkin Dermatology的唯一实益拥有人。
Itai Arkin currently serves as Investment Manager at Arkin Holdings Ltd. Mr. Itai Arkin holds a B.A. in biness administration (cum laude) from Interdisciplinary Center, Herzliya, Israel, and an MBA (cum laude) from Tel Aviv University. Mr. Itai Arkin is the son of Mr. Moshe Arkin, the chairman of board of directors and sole beneficial owner of Arkin Dermatology, controlling shareholder. - Itai Arkin在我们的首次公开募股定价后立即成为我们的董事会成员。Itai Arkin先生目前担任Arkin Holdings Ltd.的投资经理和Exalenz Bioscience Ltd.的董事会成员。Itai Arkin自2014年3月起担任以色列领先的医疗科技投资公司AccelMed和领先的梦百合对冲基金Sphera Global梦百合的投资委员会成员。Itai Arkin先生拥有以色列赫兹利亚跨学科中心工商管理学士学位和特拉维夫大学工商管理硕士学位（优等生）。Itai Arkin先生是我们董事会主席Moshe Arkin先生的儿子，也是我们控股股东Arkin Dermatology的唯一实益拥有人。
- Itai Arkin currently serves as Investment Manager at Arkin Holdings Ltd. Mr. Itai Arkin holds a B.A. in biness administration (cum laude) from Interdisciplinary Center, Herzliya, Israel, and an MBA (cum laude) from Tel Aviv University. Mr. Itai Arkin is the son of Mr. Moshe Arkin, the chairman of board of directors and sole beneficial owner of Arkin Dermatology, controlling shareholder.
- Hani Lerman
-
Hani Lerman在我们的首次公开募股定价后立即成为我们的董事会成员。Lerman女士自2015年起担任Arkin Holdings首席财务官。从2010年到2014年，Lerman女士担任Sansa Security F/K/A Discretix Technologies的首席财务官，从2006年到2010年，她担任Storwize的首席财务官，该公司于2010年被IBM收购。她是Exalenz Bioscience和Sphera Global梦百合的董事会成员。她持有以色列特拉维夫大学（Tel-Aviv University）的工商管理硕士学位，主修金融，以及以色列特拉维夫大学（Tel-Aviv University，Israel）的经济学和会计学学士学位。
Hani Lerman has served as chief financial officer at Arkin Holdings since 2015. From 2010 until 2014, Ms. Lerman served as chief financial officer of Sansa Security (f/k/a Discretix Technologies), and from 2006 until 2010, she served as chief financial officer of Storwize, which was acquired by IBM in 2010. She served as a board member of Exalenz Bioscience and of Sphera Global Healthcare. She holds a Master's degree in biness administration with a major in finance from Tel Aviv University, Israel, and a B.A. in economics and accounting from Tel Aviv University, Israel. - Hani Lerman在我们的首次公开募股定价后立即成为我们的董事会成员。Lerman女士自2015年起担任Arkin Holdings首席财务官。从2010年到2014年，Lerman女士担任Sansa Security F/K/A Discretix Technologies的首席财务官，从2006年到2010年，她担任Storwize的首席财务官，该公司于2010年被IBM收购。她是Exalenz Bioscience和Sphera Global梦百合的董事会成员。她持有以色列特拉维夫大学（Tel-Aviv University）的工商管理硕士学位，主修金融，以及以色列特拉维夫大学（Tel-Aviv University，Israel）的经济学和会计学学士学位。
- Hani Lerman has served as chief financial officer at Arkin Holdings since 2015. From 2010 until 2014, Ms. Lerman served as chief financial officer of Sansa Security (f/k/a Discretix Technologies), and from 2006 until 2010, she served as chief financial officer of Storwize, which was acquired by IBM in 2010. She served as a board member of Exalenz Bioscience and of Sphera Global Healthcare. She holds a Master's degree in biness administration with a major in finance from Tel Aviv University, Israel, and a B.A. in economics and accounting from Tel Aviv University, Israel.
- Yuval Yanai
-
Yuval Yanai从2005年9月到2014年3月，Yanai先生担任基文影像公司（Given Imaging Ltd.）的高级副总裁兼首席财务官。从2000年10月到2005年8月，他担任库尔工业公司（Koor Industries Ltd.）的高级副总裁兼首席财务官，其为以色列最大的控股公司之一。在这之前，从1998年4月到2000年9月，他担任NICE Systems Ltd.的副总裁兼首席财务官，这是一家以色列的交互洞察（Insight from Interactions）系统的全球供应商，从1991年到1998年4月，他担任爱尔新特公司（Elscint Ltd.）的财务部副总裁兼首席财务官，这是一家致力于医疗成像设备制造的前以色列公司，其被该行业规模更大的公司收购。他于1985年加入Elscint，并担任公司财务总管与公司财务主管至1991年。在这之前，Yanai先生担任Citycon Oj、Starplast Industries Ltd.、 Adama Ltd.（以前该公司叫Makteshim-Agan Industries Ltd.）、 ECI Telecom Ltd.、Equity One, Inc.、 BVR Systems Ltd.、Tadiran Communication Ltd.、 The Elisra Group与Telrad Networks Ltd.。Yanai先生在特拉维夫大学（Tel-Aviv University）获得会计学与经济学理学学士学位。
Yuval Yanai served as Senior Vice President and Chief Financial Officer of Given Imaging Ltd. from September 2005 through March 2014. From October 2000 through August 2005 Mr. Yanai served as Senior Vice President and Chief Financial Officer of Koor Industries Ltd. Prior to that, from April 1998 to September 2000 Mr. Yanai served as Vice President and Chief Financial Officer of NICE Systems Ltd., an Israeli global provider of Insight from Interactions, and, from 1991 to April 1998 he served as the Vice President, Finance and Chief Financial Officer of Elscint Ltd., a former Israeli company engaged in the developing and manufacturing of medical imaging devices. Mr. Yanai joined Elscint in 1985 and served as Corporate Controller and Corporate Treasurer through 1991. Mr. Yanai also serves as an external director within the meaning of the Israeli Companies Law of Hadassah Medical Organization, and serves as the Chairman of its finance and compensation committees and as a member of its tenders and donation committee. Mr. Yanai also serves as an external director within the meaning of the Israeli Companies Law of S&P Global Maalot. Mr. Yanai also serves as an external director (within the meaning of the Israeli Companies Law) of Clal Biotechnology Industries and serves as the Chairman of its audit and financial reporting committees, and as a member of its compensation committee. Mr. Yanai also serves as a member of the board of directors of Nobio Ltd. and BRH Medical Ltd. Previously, Mr. Yanai served as an external director (within the meaning of the Israeli Companies Law) of Mazor Robotics Ltd. and Medical Compression Systems Ltd. and as a director of Medigus Ltd. Mr. Yanai also served as a director of Macrocure Ltd., Citycon Oj, Starplast Industries Ltd., Adama Ltd. (formerly Makteshim-Agan Industries Ltd.), ECI Telecom Ltd., Equity One, Inc., BVR Systems Ltd., Tadiran Communication Ltd., The Elisra Group, Telrad Networks Ltd. and Medical Compression Systems (D.B.N) Ltd. Mr. Yanai holds a B.Sc. degree in Accounting and Economics from Tel-Aviv University. - Yuval Yanai从2005年9月到2014年3月，Yanai先生担任基文影像公司（Given Imaging Ltd.）的高级副总裁兼首席财务官。从2000年10月到2005年8月，他担任库尔工业公司（Koor Industries Ltd.）的高级副总裁兼首席财务官，其为以色列最大的控股公司之一。在这之前，从1998年4月到2000年9月，他担任NICE Systems Ltd.的副总裁兼首席财务官，这是一家以色列的交互洞察（Insight from Interactions）系统的全球供应商，从1991年到1998年4月，他担任爱尔新特公司（Elscint Ltd.）的财务部副总裁兼首席财务官，这是一家致力于医疗成像设备制造的前以色列公司，其被该行业规模更大的公司收购。他于1985年加入Elscint，并担任公司财务总管与公司财务主管至1991年。在这之前，Yanai先生担任Citycon Oj、Starplast Industries Ltd.、 Adama Ltd.（以前该公司叫Makteshim-Agan Industries Ltd.）、 ECI Telecom Ltd.、Equity One, Inc.、 BVR Systems Ltd.、Tadiran Communication Ltd.、 The Elisra Group与Telrad Networks Ltd.。Yanai先生在特拉维夫大学（Tel-Aviv University）获得会计学与经济学理学学士学位。
- Yuval Yanai served as Senior Vice President and Chief Financial Officer of Given Imaging Ltd. from September 2005 through March 2014. From October 2000 through August 2005 Mr. Yanai served as Senior Vice President and Chief Financial Officer of Koor Industries Ltd. Prior to that, from April 1998 to September 2000 Mr. Yanai served as Vice President and Chief Financial Officer of NICE Systems Ltd., an Israeli global provider of Insight from Interactions, and, from 1991 to April 1998 he served as the Vice President, Finance and Chief Financial Officer of Elscint Ltd., a former Israeli company engaged in the developing and manufacturing of medical imaging devices. Mr. Yanai joined Elscint in 1985 and served as Corporate Controller and Corporate Treasurer through 1991. Mr. Yanai also serves as an external director within the meaning of the Israeli Companies Law of Hadassah Medical Organization, and serves as the Chairman of its finance and compensation committees and as a member of its tenders and donation committee. Mr. Yanai also serves as an external director within the meaning of the Israeli Companies Law of S&P Global Maalot. Mr. Yanai also serves as an external director (within the meaning of the Israeli Companies Law) of Clal Biotechnology Industries and serves as the Chairman of its audit and financial reporting committees, and as a member of its compensation committee. Mr. Yanai also serves as a member of the board of directors of Nobio Ltd. and BRH Medical Ltd. Previously, Mr. Yanai served as an external director (within the meaning of the Israeli Companies Law) of Mazor Robotics Ltd. and Medical Compression Systems Ltd. and as a director of Medigus Ltd. Mr. Yanai also served as a director of Macrocure Ltd., Citycon Oj, Starplast Industries Ltd., Adama Ltd. (formerly Makteshim-Agan Industries Ltd.), ECI Telecom Ltd., Equity One, Inc., BVR Systems Ltd., Tadiran Communication Ltd., The Elisra Group, Telrad Networks Ltd. and Medical Compression Systems (D.B.N) Ltd. Mr. Yanai holds a B.Sc. degree in Accounting and Economics from Tel-Aviv University.
- Moshe Arkin
-
Moshe Arkin自2014年以来一直担任我们的董事会主席。Moshe Arkin目前是几家私人制药和医疗设备公司的董事，其中包括Exalenz Bioscience Ltd.，该公司自2006年以来一直是胃肠和肝脏疾病先进系统的开发商，Sonivie Ltd.是一家开发肺动脉高压治疗系统的公司，Digma Medical，一家开发治疗2型糖尿病和其他代谢综合征疾病中存在的胰岛素抵抗的系统的公司，以及一家开发心脏瓣膜设备的公司ValCare Medical。从2005年到2008年，Moshe Arkin先生担任Perrigo Company的仿制药主管，并从2005年到2011年担任其董事会副主席。在加入我们之前，Moshe Arkin先生曾担任CCAM Biotherapeutics Ltd.的董事，该公司从2012年到2015年被默克制药公司收购，专注于发现和开发治疗癌症的新型免疫疗法从1972年Agis Industries Ltd.成立到2005年被Perrigo Company收购，Moshe Arkin先生一直担任其董事长。Moshe Arkin先生拥有以色列特拉维夫大学心理学学士学位。
Moshe Arkin has served as interim chief executive officer since January 1, 2025 and has served as chairman of board of directors since 2014. In May 2022, Mr. Moshe Arkin's role was expanded to Executive Chairman to reflect Mr. Arkin's expanded role at the Company. Mr. Moshe Arkin currently sits on the board of directors of several private pharmaceutical and medical device companies including SoniVie Ltd., a company developing systems for the treatment of pulmonary arterial hypertension, Digma Medical, a company developing systems to treat insulin resistance present in type 2 diabetes and other metabolic syndrome diseases, and Valcare Medical, a company developing heart valve devices. From 2005 to 2008, Mr. Moshe Arkin served as the head of generics at Perrigo Company and from 2005 until 2011 as the vice chairman of its board of directors. Prior to joining , Mr. Moshe Arkin served as a director of cCAM Biotherapeutics Ltd., a company foced on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck & Co., Inc. Mr. Moshe Arkin served as chairman of Agis Indtries Ltd. from its inception in 1972 until its acquisition by Perrigo Company in 2005. Mr. Moshe Arkin holds a B.A. in psychology from the Tel Aviv University, Israel. - Moshe Arkin自2014年以来一直担任我们的董事会主席。Moshe Arkin目前是几家私人制药和医疗设备公司的董事，其中包括Exalenz Bioscience Ltd.，该公司自2006年以来一直是胃肠和肝脏疾病先进系统的开发商，Sonivie Ltd.是一家开发肺动脉高压治疗系统的公司，Digma Medical，一家开发治疗2型糖尿病和其他代谢综合征疾病中存在的胰岛素抵抗的系统的公司，以及一家开发心脏瓣膜设备的公司ValCare Medical。从2005年到2008年，Moshe Arkin先生担任Perrigo Company的仿制药主管，并从2005年到2011年担任其董事会副主席。在加入我们之前，Moshe Arkin先生曾担任CCAM Biotherapeutics Ltd.的董事，该公司从2012年到2015年被默克制药公司收购，专注于发现和开发治疗癌症的新型免疫疗法从1972年Agis Industries Ltd.成立到2005年被Perrigo Company收购，Moshe Arkin先生一直担任其董事长。Moshe Arkin先生拥有以色列特拉维夫大学心理学学士学位。
- Moshe Arkin has served as interim chief executive officer since January 1, 2025 and has served as chairman of board of directors since 2014. In May 2022, Mr. Moshe Arkin's role was expanded to Executive Chairman to reflect Mr. Arkin's expanded role at the Company. Mr. Moshe Arkin currently sits on the board of directors of several private pharmaceutical and medical device companies including SoniVie Ltd., a company developing systems for the treatment of pulmonary arterial hypertension, Digma Medical, a company developing systems to treat insulin resistance present in type 2 diabetes and other metabolic syndrome diseases, and Valcare Medical, a company developing heart valve devices. From 2005 to 2008, Mr. Moshe Arkin served as the head of generics at Perrigo Company and from 2005 until 2011 as the vice chairman of its board of directors. Prior to joining , Mr. Moshe Arkin served as a director of cCAM Biotherapeutics Ltd., a company foced on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck & Co., Inc. Mr. Moshe Arkin served as chairman of Agis Indtries Ltd. from its inception in 1972 until its acquisition by Perrigo Company in 2005. Mr. Moshe Arkin holds a B.A. in psychology from the Tel Aviv University, Israel.
- Ran Gottfried
-
Ran Gottfried，2006年2月以来，一直担任Perrigo的董事。2006年至2008年12月，他担任Powerpaper Ltd.的董事长、首席执行官，这是微电化妆品和药物贴片的顶尖开发制造商。1975年以来，他在以色列和欧洲的多个私营企业担任过首席执行官、顾问、董事，涉及零售与分销、制药、电信等领域。2001-2005，他担任Magnolia Silver Jewelry, Ltd.的董事长。2004-2007，他还曾担任Careline-Neca的顾问，这是Perrigo以色列子公司的消费品部门。2003年起，他担任Agis的董事，直到2005年它被Perrigo收购；2005年至2010年4月，担任Bezeq的董事，这是以色列顶尖的电信提供商。他目前居住在以色列。
Ran Gottfried has served as a chief executive officer, consultant and director of private companies in Israel and Europe in the areas of retail and distribution of pharmaceuticals, consumer and hoehold products. Mr. Gottfried served as a director of Perrigo Company from 2006 until 2015. From 2006 until 2008, Mr. Gottfried served as chairman and chief executive officer of Porpaper Ltd., a leading developer and manufacturer of micro electrical cosmetic and pharmaceutical patches. From 2005 until 2010, Mr. Gottfried served as a director of Bezeq, Israel's leading telecommunications provider and from 2003 until its acquisition by Perrigo Company in 2005, Mr. Gottfried served as a director of Agis Indtries Ltd. He served as a director at Shufersal Ltd from 2018 until 2022. - Ran Gottfried，2006年2月以来，一直担任Perrigo的董事。2006年至2008年12月，他担任Powerpaper Ltd.的董事长、首席执行官，这是微电化妆品和药物贴片的顶尖开发制造商。1975年以来，他在以色列和欧洲的多个私营企业担任过首席执行官、顾问、董事，涉及零售与分销、制药、电信等领域。2001-2005，他担任Magnolia Silver Jewelry, Ltd.的董事长。2004-2007，他还曾担任Careline-Neca的顾问，这是Perrigo以色列子公司的消费品部门。2003年起，他担任Agis的董事，直到2005年它被Perrigo收购；2005年至2010年4月，担任Bezeq的董事，这是以色列顶尖的电信提供商。他目前居住在以色列。
- Ran Gottfried has served as a chief executive officer, consultant and director of private companies in Israel and Europe in the areas of retail and distribution of pharmaceuticals, consumer and hoehold products. Mr. Gottfried served as a director of Perrigo Company from 2006 until 2015. From 2006 until 2008, Mr. Gottfried served as chairman and chief executive officer of Porpaper Ltd., a leading developer and manufacturer of micro electrical cosmetic and pharmaceutical patches. From 2005 until 2010, Mr. Gottfried served as a director of Bezeq, Israel's leading telecommunications provider and from 2003 until its acquisition by Perrigo Company in 2005, Mr. Gottfried served as a director of Agis Indtries Ltd. He served as a director at Shufersal Ltd from 2018 until 2022.
- Sharon Kochan
-
Sharon Kochan,Kochan于2012年8月被任命为International执行副总裁和总经理。他从2007年3月到2012年7月担任Rx Pharmaceuticals执行副总裁和总经理；2005年到2007年3月担任业务开发和战略高级副总裁。Kochan从2001年到2005年（公司收购Agis）之前担任Agis Industries -1983 Ltd.业务开发副总裁。
Sharon Kochan was named Executive Vice President and President, RX Pharmaceuticals in October 2018. He served as Executive Vice President and President, Branded Consumer Healthcare International from February 2017 to October 2018. He served as Executive Vice President and General Manager, Consumer Healthcare International from August 2012 to February 2017. He served as Executive Vice President, General Manager of Prescription Pharmaceuticals from March 2007 to July 2012 and as Senior Vice President of Business Development and Strategy from March 2005 to March 2007. Mr. Kochan was Vice President, Business Development of Agis Industries -1983 Ltd. from July 2001 until the acquisition of Agis by the Company in March 2005. - Sharon Kochan,Kochan于2012年8月被任命为International执行副总裁和总经理。他从2007年3月到2012年7月担任Rx Pharmaceuticals执行副总裁和总经理；2005年到2007年3月担任业务开发和战略高级副总裁。Kochan从2001年到2005年（公司收购Agis）之前担任Agis Industries -1983 Ltd.业务开发副总裁。
- Sharon Kochan was named Executive Vice President and President, RX Pharmaceuticals in October 2018. He served as Executive Vice President and President, Branded Consumer Healthcare International from February 2017 to October 2018. He served as Executive Vice President and General Manager, Consumer Healthcare International from August 2012 to February 2017. He served as Executive Vice President, General Manager of Prescription Pharmaceuticals from March 2007 to July 2012 and as Senior Vice President of Business Development and Strategy from March 2005 to March 2007. Mr. Kochan was Vice President, Business Development of Agis Industries -1983 Ltd. from July 2001 until the acquisition of Agis by the Company in March 2005.
高管简历
中英对照 | 中文 | 英文- Ofer Toledano
自2004年以来，Ofer Toledano一直是我们研究与开发的Vice President。加入Sol-Gel公司之前，Toledano博士从1998年到2004年担任Adama Agricultural SolutionsLtd.（原名Makhteshim Agan Industries Ltd.）的配方部经理，该公司是一家以色列作物保护产品制造商和分销商。Toledano博士拥有以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem，Israel）化学博士学位。
Ofer Toledano has served as vice president of research and development since 2004. Prior to joining Sol Gel, Dr. Toledano served as manager of the formulation department at ADAMA Agricultural Solutions Ltd. (formerly known as Makhteshim Agan Indtries Ltd.), an Israeli manufacturer and distributor of crop protection products from 1998 until 2004. Dr. Toledano holds a Ph.D. in chemistry from The Hebrew University of Jeralem, Israel.- 自2004年以来，Ofer Toledano一直是我们研究与开发的Vice President。加入Sol-Gel公司之前，Toledano博士从1998年到2004年担任Adama Agricultural SolutionsLtd.（原名Makhteshim Agan Industries Ltd.）的配方部经理，该公司是一家以色列作物保护产品制造商和分销商。Toledano博士拥有以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem，Israel）化学博士学位。
- Ofer Toledano has served as vice president of research and development since 2004. Prior to joining Sol Gel, Dr. Toledano served as manager of the formulation department at ADAMA Agricultural Solutions Ltd. (formerly known as Makhteshim Agan Indtries Ltd.), an Israeli manufacturer and distributor of crop protection products from 1998 until 2004. Dr. Toledano holds a Ph.D. in chemistry from The Hebrew University of Jeralem, Israel.
- Ofra Levy Hacham
Ofra Levy Hacham自2018年以来一直担任我们的临床保证和监管事务Vice President，并于2011年至2018年担任我们的质量和监管事务Vice President。加入Sol-Gel之前，Levy-Hacham从2010年到2011年担任Biotechnology General Ltd.（Ferring Pharmaceuticals Ltd.的全资子公司，一家完全集成的生物制药服务私人公司）科学专家和项目经理。从2005年到2010年，Levy-Hacham博士担任Healor Ltd.的化学、制造和控制Vice President，该公司是一家私人公司，从事治疗各种皮肤病的疗法的开发。Levy-Hacham博士拥有以色列Technion-Israel Institute of Technology的化学博士学位。
Ofra Levy Hacham has served as vice president of quality, clinical and regulatory affairs since January 2024, as vice president of clinical and regulatory affairs since 2018, and as vice president of quality and regulatory affairs from 2011 to 2018. Prior to joining Sol Gel, Dr. Levy Hacham served as a scientific specialist and project manager at Biotechnology General Ltd., a wholly owned subsidiary of Ferring Pharmaceuticals Ltd., and a fully integrated biopharmaceutical services private company from 2010 until 2011. From 2005 until 2010, Dr. Levy Hacham served as vice president chemistry, manufacturing and controls at HealOr Ltd., a private company engaging in the development of therapeutics for the treatment of vario skin disorders. Dr. Levy Hacham holds a Ph.D. in chemistry from The Technion – Israel Institute of Technology, Israel.- Ofra Levy Hacham自2018年以来一直担任我们的临床保证和监管事务Vice President，并于2011年至2018年担任我们的质量和监管事务Vice President。加入Sol-Gel之前，Levy-Hacham从2010年到2011年担任Biotechnology General Ltd.（Ferring Pharmaceuticals Ltd.的全资子公司，一家完全集成的生物制药服务私人公司）科学专家和项目经理。从2005年到2010年，Levy-Hacham博士担任Healor Ltd.的化学、制造和控制Vice President，该公司是一家私人公司，从事治疗各种皮肤病的疗法的开发。Levy-Hacham博士拥有以色列Technion-Israel Institute of Technology的化学博士学位。
- Ofra Levy Hacham has served as vice president of quality, clinical and regulatory affairs since January 2024, as vice president of clinical and regulatory affairs since 2018, and as vice president of quality and regulatory affairs from 2011 to 2018. Prior to joining Sol Gel, Dr. Levy Hacham served as a scientific specialist and project manager at Biotechnology General Ltd., a wholly owned subsidiary of Ferring Pharmaceuticals Ltd., and a fully integrated biopharmaceutical services private company from 2010 until 2011. From 2005 until 2010, Dr. Levy Hacham served as vice president chemistry, manufacturing and controls at HealOr Ltd., a private company engaging in the development of therapeutics for the treatment of vario skin disorders. Dr. Levy Hacham holds a Ph.D. in chemistry from The Technion – Israel Institute of Technology, Israel.
- Itzik Yosef
Itzik Yosef自2016年8月起担任我们的运营Vice President。自2010年加入公司以来，Yosef博士担任多个职位，包括运营主管。Yosef博士拥有以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem，Israel）化学博士学位。
Itzik Yosef has served as Chief Operating Officer since 2020, and as vice president of operations from 2016 until 2020. Since joining in 2010, Dr. Yosef held vario positions including as head of operations. Dr. Yosef holds a Ph.D. in chemistry from The Hebrew University of Jeralem, Israel.- Itzik Yosef自2016年8月起担任我们的运营Vice President。自2010年加入公司以来，Yosef博士担任多个职位，包括运营主管。Yosef博士拥有以色列耶路撒冷希伯来大学（Hebrew University of Jerusalem，Israel）化学博士学位。
- Itzik Yosef has served as Chief Operating Officer since 2020, and as vice president of operations from 2016 until 2020. Since joining in 2010, Dr. Yosef held vario positions including as head of operations. Dr. Yosef holds a Ph.D. in chemistry from The Hebrew University of Jeralem, Israel.
- Michael Glezin
Michael Glezin自2025年1月起担任Biness首席执行官，自2022年9月起担任Biness Development副总裁。在加入Sol Gel之前，Glezin先生曾于2011年至2022年担任Generic Biness Development负责人，并在国际专业制药公司Dexcel Pharma担任多个其他Biness开发职位。Glezin先生拥有以色列海法大学与中国通宜大学合作的高级管理人员MBA学位，以及海法大学的经济和管理学士学位。
Michael Glezin has served as Chief Biness Officer since January 2025, and as vice president of biness development from September 2022. Prior to joining Sol Gel, Mr. Glezin served from 2011 to 2022 as the Head of Generic Biness Development and in vario other biness development positions at Dexcel Pharma, an international specialty pharmaceutical company. Mr. Glezin holds an Executive MBA from Haifa University in Israel in partnership with Tongi University in China and a bachelor's degree in economics and management from Haifa University.- Michael Glezin自2025年1月起担任Biness首席执行官，自2022年9月起担任Biness Development副总裁。在加入Sol Gel之前，Glezin先生曾于2011年至2022年担任Generic Biness Development负责人，并在国际专业制药公司Dexcel Pharma担任多个其他Biness开发职位。Glezin先生拥有以色列海法大学与中国通宜大学合作的高级管理人员MBA学位，以及海法大学的经济和管理学士学位。
- Michael Glezin has served as Chief Biness Officer since January 2025, and as vice president of biness development from September 2022. Prior to joining Sol Gel, Mr. Glezin served from 2011 to 2022 as the Head of Generic Biness Development and in vario other biness development positions at Dexcel Pharma, an international specialty pharmaceutical company. Mr. Glezin holds an Executive MBA from Haifa University in Israel in partnership with Tongi University in China and a bachelor's degree in economics and management from Haifa University.
- Eyal Ben Or
Eyal Ben Or自2024年7月起担任首席财务官。Ben Or先生于2017年加入Sol Gel，曾担任该组织的财务总监。在加入Sol Gel之前，Ben Or先生曾在Mobileye N.V.（NYSE：MBLY）担任财务报告职务，并在毕马威会计师事务所的鉴证部门担任过多个职务。Ben Or先生拥有以色列管理学院biness administration and financial management硕士学位和会计及biness administration学士学位，注册会计师。
Eyal Ben Or has served as Chief Financial Officer since July 2024. Mr. Ben Or joined Sol Gel in 2017 and served the organization as Director of Finance. Prior to joining Sol Gel, Mr. Ben Or served in financial reporting roles at Mobileye N.V. (NYSE: MBLY) and in several roles in the assurance department of KPMG. Mr. Ben Or holds a master's degree in biness administration and financial management and a bachelor's degree in accounting and biness administration from the College of Management in Israel and is a certified public accountant.- Eyal Ben Or自2024年7月起担任首席财务官。Ben Or先生于2017年加入Sol Gel，曾担任该组织的财务总监。在加入Sol Gel之前，Ben Or先生曾在Mobileye N.V.（NYSE：MBLY）担任财务报告职务，并在毕马威会计师事务所的鉴证部门担任过多个职务。Ben Or先生拥有以色列管理学院biness administration and financial management硕士学位和会计及biness administration学士学位，注册会计师。
- Eyal Ben Or has served as Chief Financial Officer since July 2024. Mr. Ben Or joined Sol Gel in 2017 and served the organization as Director of Finance. Prior to joining Sol Gel, Mr. Ben Or served in financial reporting roles at Mobileye N.V. (NYSE: MBLY) and in several roles in the assurance department of KPMG. Mr. Ben Or holds a master's degree in biness administration and financial management and a bachelor's degree in accounting and biness administration from the College of Management in Israel and is a certified public accountant.
- Moshe Arkin
Moshe Arkin自2014年以来一直担任我们的董事会主席。Moshe Arkin目前是几家私人制药和医疗设备公司的董事，其中包括Exalenz Bioscience Ltd.，该公司自2006年以来一直是胃肠和肝脏疾病先进系统的开发商，Sonivie Ltd.是一家开发肺动脉高压治疗系统的公司，Digma Medical，一家开发治疗2型糖尿病和其他代谢综合征疾病中存在的胰岛素抵抗的系统的公司，以及一家开发心脏瓣膜设备的公司ValCare Medical。从2005年到2008年，Moshe Arkin先生担任Perrigo Company的仿制药主管，并从2005年到2011年担任其董事会副主席。在加入我们之前，Moshe Arkin先生曾担任CCAM Biotherapeutics Ltd.的董事，该公司从2012年到2015年被默克制药公司收购，专注于发现和开发治疗癌症的新型免疫疗法从1972年Agis Industries Ltd.成立到2005年被Perrigo Company收购，Moshe Arkin先生一直担任其董事长。Moshe Arkin先生拥有以色列特拉维夫大学心理学学士学位。
Moshe Arkin has served as interim chief executive officer since January 1, 2025 and has served as chairman of board of directors since 2014. In May 2022, Mr. Moshe Arkin's role was expanded to Executive Chairman to reflect Mr. Arkin's expanded role at the Company. Mr. Moshe Arkin currently sits on the board of directors of several private pharmaceutical and medical device companies including SoniVie Ltd., a company developing systems for the treatment of pulmonary arterial hypertension, Digma Medical, a company developing systems to treat insulin resistance present in type 2 diabetes and other metabolic syndrome diseases, and Valcare Medical, a company developing heart valve devices. From 2005 to 2008, Mr. Moshe Arkin served as the head of generics at Perrigo Company and from 2005 until 2011 as the vice chairman of its board of directors. Prior to joining , Mr. Moshe Arkin served as a director of cCAM Biotherapeutics Ltd., a company foced on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck & Co., Inc. Mr. Moshe Arkin served as chairman of Agis Indtries Ltd. from its inception in 1972 until its acquisition by Perrigo Company in 2005. Mr. Moshe Arkin holds a B.A. in psychology from the Tel Aviv University, Israel.- Moshe Arkin自2014年以来一直担任我们的董事会主席。Moshe Arkin目前是几家私人制药和医疗设备公司的董事，其中包括Exalenz Bioscience Ltd.，该公司自2006年以来一直是胃肠和肝脏疾病先进系统的开发商，Sonivie Ltd.是一家开发肺动脉高压治疗系统的公司，Digma Medical，一家开发治疗2型糖尿病和其他代谢综合征疾病中存在的胰岛素抵抗的系统的公司，以及一家开发心脏瓣膜设备的公司ValCare Medical。从2005年到2008年，Moshe Arkin先生担任Perrigo Company的仿制药主管，并从2005年到2011年担任其董事会副主席。在加入我们之前，Moshe Arkin先生曾担任CCAM Biotherapeutics Ltd.的董事，该公司从2012年到2015年被默克制药公司收购，专注于发现和开发治疗癌症的新型免疫疗法从1972年Agis Industries Ltd.成立到2005年被Perrigo Company收购，Moshe Arkin先生一直担任其董事长。Moshe Arkin先生拥有以色列特拉维夫大学心理学学士学位。
- Moshe Arkin has served as interim chief executive officer since January 1, 2025 and has served as chairman of board of directors since 2014. In May 2022, Mr. Moshe Arkin's role was expanded to Executive Chairman to reflect Mr. Arkin's expanded role at the Company. Mr. Moshe Arkin currently sits on the board of directors of several private pharmaceutical and medical device companies including SoniVie Ltd., a company developing systems for the treatment of pulmonary arterial hypertension, Digma Medical, a company developing systems to treat insulin resistance present in type 2 diabetes and other metabolic syndrome diseases, and Valcare Medical, a company developing heart valve devices. From 2005 to 2008, Mr. Moshe Arkin served as the head of generics at Perrigo Company and from 2005 until 2011 as the vice chairman of its board of directors. Prior to joining , Mr. Moshe Arkin served as a director of cCAM Biotherapeutics Ltd., a company foced on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck & Co., Inc. Mr. Moshe Arkin served as chairman of Agis Indtries Ltd. from its inception in 1972 until its acquisition by Perrigo Company in 2005. Mr. Moshe Arkin holds a B.A. in psychology from the Tel Aviv University, Israel.